Gene · 83990
Papers4,271
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
241 to 260 of 4,271
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
Combination of mutations in genes controlling DNA repair and high mutational load plays a prognostic role in pancreatic ductal adenocarcinoma (PDAC): a retrospective real-life study in Sardinian population. | J Transl Med | 2024 | 38280995 | PubTator, text mining | PubMed |
| Trends and Age-Period-Cohort Effect on Incidence of Male Breast Cancer from 1980 to 2019 in Taiwan and the USA. | Cancers (Basel) | 2024 | 38275884 | PubTator, text mining | PubMed |
| High-Grade Serous Ovarian Cancer-A Risk Factor Puzzle and Screening Fugitive. | Biomedicines | 2024 | 38275400 | PubTator, text mining | PubMed |
| FANCJ promotes PARP1 activity during DNA replication that is essential in BRCA1 deficient cells. | bioRxiv | 2024 | 38260529 | PubTator, text mining | PubMed |
| Translation into Clinical Practice of the G1-G7 Molecular Subgroup Classification of Glioblastoma: Comprehensive Demographic and Molecular Pathway Profiling. | Cancers (Basel) | 2024 | 38254850 | PubTator, text mining | PubMed |
| How to Integrate Prostate Cancer Biomarkers in Urology Clinical Practice: An Update. | Cancers (Basel) | 2024 | 38254807 | PubTator, text mining | PubMed |
| Prevalence and Distribution of MUTYH Pathogenic Variants, Is There a Relation with an Increased Risk of Breast Cancer? | Cancers (Basel) | 2024 | 38254803 | PubTator, text mining | PubMed |
| ATR inhibition using gartisertib enhances cell death and synergises with temozolomide and radiation in patient-derived glioblastoma cell lines. | Oncotarget | 2024 | 38227740 | PubTator, text mining | PubMed |
| BRCA2, PALB2, RECQL4 Germline Pathogenic Variants, and Somatic TP53 Mutation in Triple Metachronous Malignancies: A Case Report and Literature Review. | Int Med Case Rep J | 2024 | 38223534 | PubTator, text mining | PubMed |
| Genomic and transcriptomic analysis of breast cancer identifies novel signatures associated with response to neoadjuvant chemotherapy. | Genome Med | 2024 | 38217005 | PubTator, text mining | PubMed |
| Preclinical exploration of the DNA damage response pathway using the interactive neuroblastoma cell line explorer CLEAN. | NAR Cancer | 2024 | 38213997 | PubTator, text mining | PubMed |
| Radiosensitization of Osteosarcoma Cells Using the PARP Inhibitor Olaparib Combined with X-rays or Carbon Ions. | J Cancer | 2024 | 38213724 | PubTator, text mining | PubMed |
| Development of PARP inhibitors in advanced prostate cancer. | Ther Adv Med Oncol | 2024 | 38205078 | PubTator, text mining | PubMed |
| Guide for phenotype-specific profiling of DNA G-quadruplex-regulated genes. | STAR Protoc | 2024 | 38198280 | PubTator, text mining | PubMed |
| A novel targeted NGS panel identifies numerous homologous recombination deficiency (HRD)-associated gene mutations in addition to known BRCA mutations. | Diagn Pathol | 2024 | 38184614 | PubTator, text mining | PubMed |
| Biology-driven therapy advances in high-grade serous ovarian cancer. | J Clin Invest | 2024 | 38165032 | PubTator, text mining | PubMed |
| Anthracycline-related cardiotoxicity in patients with breast cancer harboring mutational signature of homologous recombination deficiency (HRD). | ESMO Open | 2024 | 38118367 | PubTator, text mining | PubMed |
| Isolation and detection of DNA-protein crosslinks in mammalian cells. | Nucleic Acids Res | 2024 | 38084926 | PubTator, text mining | PubMed |
| Clinical implications of incorporating genetic and non-genetic risk factors in CanRisk-based breast cancer risk prediction. | Breast | 2024 | 38061307 | PubTator, text mining | PubMed |
| First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. | Nat Med | 2024 | 38049622 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/83990/papers?page=13